Compare KELYB & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | BBNX |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | 5570 | 423 |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.9M | 493.1M |
| IPO Year | N/A | N/A |
| Metric | KELYB | BBNX |
|---|---|---|
| Price | $15.59 | $8.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $24.78 |
| AVG Volume (30 Days) | 16.6K | ★ 908.9K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.72 | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.38 | $9.37 |
| 52 Week High | $125.00 | $32.71 |
| Indicator | KELYB | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 25.01 |
| Support Level | $11.66 | N/A |
| Resistance Level | $21.46 | $11.92 |
| Average True Range (ATR) | 1.00 | 0.70 |
| MACD | 0.32 | 0.02 |
| Stochastic Oscillator | 53.86 | 2.10 |
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services to a diverse group of clients operating in the Americas, Europe, and the Asia-Pacific region across various industries. The company's reportable segments are: Enterprise Talent Management, Science, Engineering and Technology, and Education. Maximum revenue is generated from its Enterprise Talent Management segment, which delivers temporary staffing, outcome-based, and permanent placement services focused on light industrial, contact center, and office and clerical specialties in North America across various industries. It also provides talent supply chain and workforce talent solutions, including MSP, RPO, and PPO solutions to its clients. Geographically, it derives key revenue from the USA.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.